New antibiotic shows promise for newborns with dangerous infections

NCT ID NCT06086626

Completed Disease control Sponsor: Shionogi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the antibiotic cefiderocol works in hospitalized infants under 3 months old with suspected or confirmed gram-negative bacterial infections. Researchers measured drug levels in the blood and checked for side effects in 30 babies. The goal was to find the right dose and ensure safety, not to prove the drug cures the infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cefiderocol (an antibiotic given intravenously)
What this could lead to: If successful, this could provide a new antibiotic option for hard-to-treat bacterial infections in very young infants.
What could go wrong: This is a small, early-phase study focused on safety and dosing, not on proving the drug works. It may not lead to a new standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAM-NEGATIVE BACTERIAL INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gram-negative bacterial infections Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAM-NEGATIVE BACTERIAL INFECTIONS

Contacts and locations

Locations

Arkansas Children's Hospital

Little Rock, Arkansas, 72202, United States
Chang Gung Memorial Hospital, Linkou Department of Pediatrics

Taoyuan City, 333, Taiwan
Duke University

Durham, North Carolina, 27705, United States
Tygerberg Hospital

Cape Town, Western Cape, 8000, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.